Bio-Rad (BIO) Q2 2025 Earnings Call Transcript

Bio-Rad reported Q2 revenue of $652 million, up 2.1% reported and 1% currency-neutral, with Life Science sales up 4.9% to $263 million and operating margin still pressured by lower gross margin. Management raised 2025 guidance: currency-neutral revenue to flat-1%, Life Science to flat-1%, Diagnostics to 0.5%-1.5%, and non-GAAP operating margin to 12%-13% as tariff headwinds eased to 30-40 bps from up to 130 bps. The company also completed the Stilla Technologies acquisition, lifted ddPCR growth expectations to mid-single digits, and bought back 593,508 shares for $139 million.

Analysis

BIO.B’s quarter reads as a mix of cyclical help and self-help, but the more important signal is that management is effectively monetizing volatility rather than simply surviving it. The process-chromatography pop likely pulled forward demand from later in the year, which means near-term outperformance is real but partially timing-driven; the better tell is that the company still chose to raise full-year assumptions even after normalizing for that pull-in. That implies underlying order trends are improving enough to absorb some reversion without breaking the guide.

The bigger second-order winner is IMDX, not because of any direct equity linkage, but because Bio-Rad is explicitly leaning into ddPCR as a commercialization platform rather than a pure research tool. If Bio-Rad can convert its installed assay base into a broader workflow with Continuum/QX700 and Stilla behind it, that raises the probability of a multi-year volume expansion in a niche where product differentiation matters more than price. Conversely, LH and other large diagnostics incumbents with exposure to broad-based academic and instrument demand may face a slower rebound because funding and capex remain deferred, not cancelled.

The contrarian miss is that margins may be closer to a cyclical trough than the market assumes. Tariff relief, FX tailwinds, and better manufacturing absorption are all incremental and, importantly, mostly margin-side upside rather than demand-side euphoria; that creates room for earnings revisions even if revenue stays subdued. The risk is that the process-chrom pull-in and ddPCR launch excitement create a second-half air pocket if academia remains soft and China reimbursement pressure widens beyond diabetes testing. That reversal would show up first in instrument demand and gross margin, not top-line growth.

Key Decisions for Investors

• Long BIO.B into the next 4-8 weeks on any post-earnings digestion pullback; base case is multiple support from upgraded margin guide and buybacks, with downside limited if Q3 prints roughly flat sequentially.
• Pair trade: long BIO.B / short LH for 1-3 months. BIO.B has more identifiable self-help from tariff relief, FX, and product mix, while LH is more exposed to broad diagnostics normalization with less operating leverage to margin surprises.
• Tactically long IMDX or IMDX-call spreads for 3-6 months if liquidity allows. The thesis is that Bio-Rad’s ddPCR push validates the market category and raises read-through to clinical adoption optionality; risk is execution timing and FDA delay.
• Sell downside via BIO.B put spreads expiring after the next quarter if implied vol remains elevated. The company has multiple non-linearity supports—buybacks, margin guide raise, and FX—that reduce tail risk unless China reimbursement deteriorates materially.
• Avoid chasing BIO.B above the first post-earnings gap fill; wait for either confirmation of sustained process-chrom order flow in the next print or evidence that ddPCR instruments are converting into recurring consumables rather than just launch noise.